Pay in 4 interest-free payments of $30.25 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
8)17-35(64)70)94-56-50(43(78)40(75)31(20-65)88-56)93-53-45(80)42(77)41(76)32(89-53)23-84-36(71)18-59(4
InChiKey: PDGKHKMBHVFCMG-UHFFFAOYSA-N
ROCK insufficiency attenuates ozone-induced airway hyperresponsiveness in mice
¹¹]undeca-1(10)
InChi: InChI=1S/C31H43ClF3NO2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-18-24-19-17-20-28(38-4-2)29(24)30(37)36-25-21-22-27(32)26(23-25)31(33
Cabotegravir 19218 8)17-35(64)70)94-56-50(43(78)40(75)31(20-65)88-56)93-53-45(80)42(77)41(76)32(89-53)23-84-36(71)18-59(4Cabotegravir is a potent HIV integrase inhibitor as an oral lead in tablet and long acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0. 81 M) and OAT3 (IC50 0. 41 M). IC50 value: 0. 81 M (OAT1), 0. 41 M (OAT3) Target: OAT1, OAT3Cabotegravir is a potent HIV integrase inhibitor in clinical development as an oral lead in tablet and long acting injectable for the treatment and prevention of